Prof. Manuel Guzman joins the Scientific Advisory Committee of VivaCell Biotechnology


Córdoba, September 12nd 2015. VivaCell Biotechnology España has renewed the panel of its Scientific Advisory Board with the incorporation of Dr. Manuel Guzman Pastor, Professor of Biochemistry and Molecular Biology at Complutense University of Madrid, and current President of the Spanish Society for Research on Cannabinoids (SEIC). Dr. Guzman’s research is focused on the molecular mechanisms that cannabinoids use on the brain and their effect on the regeneration, growth and cell survival in the nervous system. Dr. Guzman publications on cannabinoids and cancer have been recognized as groundbreaking by researchers worldwide and have initiated a long series of new studies in this field. In 2009 he received the award for basic research of the International Association for Cannabinoid Medicines.

Dr. Guzman joins the team of renowned scientists led by Dr. Eduardo Muñoz Professor of Immunology at University of Córdoba and VivaCell founder): Dr. Javier Fernández Ruiz (Professor of Biochemistry and Molecular Biology at Universidad Complutense of Madrid), Dr.Giovanni Appendino (Professor of Pharmaceutical Chemistry at the Università degli Studi del Piemonte Orientale in Novara Amadeo Avogadro, Italy), and Dr. Bernd Fiebich (Associate Professor, Department of Psychiatry, University of Freiburg, Germany). Additionally, VivaCell is glad to thank Dr. Olov Sterner (Professor of Organic Chemistry at the University of Lund, Switzerland) for his contribution to VivaCell SAB during the Drug Discovery phase of the Company.

With the renewal of its scientific advisory panel, Vivacell enhances its network of collaborations in the field of biomedical research on cannabinoids, and focuses the scientific strategy on the development of its compounds VCE-003 and VCE-004. Both are in preclinical stage for the treatment of neurodegenerative diseases (Huntington's, Parkinson's, Multiple Sclerosis, Amyotrophic Lateral Sclerosis) and fibrotic diseases such as Scleroderma.

Developed with DoPlanning